Figure 6.

The use of OoCs and MoCs in the investigation and evaluation of targeted drug delivery systems through passive, active, and triggered targeting strategies. i) In vitro regulation of cancer angiogenesis using a 3D microfluidic platform using MSNs loaded with or without siVEGF or siVEGFR. Adapted from^{[ 80 ]} with permission from ACS Publications. ii) A microfluidic device for encapsulating cancer cells in core–shell microcapsules, which form microtumors after incubation for 10 days, and testing NIR activated NPs. Staining for ACTIN filament, CD31, and cell nuclei showed extensive vascularization of the 3D tumors. Reproduced with permission.^{[ 101 ]} Copyright 2017, ACS Publications.